Cite
HARVARD Citation
Coleman, R. et al. (n.d.). 2022-RA-249-ESGO Overall survival results from ariel3: a phase 3 randomised, double-blind study of rucaparib vs placebo following response to platinum-based chemotherapy for recurrent ovarian carcinoma. International journal of gynecological cancer. p. A226. [Online].